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Abstract
Aim To assess whether the BI-RADS classification in MR-
Mammography (MRM) can distinguish between benign
and malignant lesions.
Material and method 207 MRM investigations were
categorised according to BI-RADS. The results were
compared to histology. All MRM studies were interpreted
by two examiners. Statistical significance for the accuracy
of MRM was calculated.
Results A significant correlation between specific histology
and MRM-tumour-morphology could not be reported. Mass
(68%) was significant for malignancy. Significance raised
with irregular shape (88%), spiculated margin (97%), rim
enhancement (98%), fast initial increase (90%), post initial
plateau (65%), and intermediate T2 result (82%). Highly
significant for benignity was an oval mass (79%), slow
initial increase (94%) and a hyperintense T2 result (77%),
also an inconspicuous MRM result (77%) was often seen in
benign histology. Symmetry (90%) and further post initial
increase (90%) were significant, whereas a regional
distribution (74%) was lowly significant for benignity.
Conclusion On basis of the BI-RADS classification an
objective comparability and statement of diagnosis could
be made highly significant. Due to the fact of false-
negative and false-positive MRM-results, histology is
necessary.
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Introduction
Breast cancer is the most common cancer in women aging
more than 40 years [1]. In early studies magnetic resonance
imaging of the breast (MRM) was used as a tool to further
characterize suspicious clinical or mammographic exami-
nations. However indications for MRM are high risk
patients, preoperative estimation of the extent of the disease
in patients with newly diagnosed breast cancer, especially
lobular invasive carcinomas, patients with breast implants,
cancer of unknown primary and the differentiation between
scar and tumour recurrence [2–7]. Breast cancers enhance
brightly compared to normal breast tissue and normal
biopsy scars, which enhance little or even not at all [8].
However, MRM techniques vary across the world. In 1999
the “Lesion Diagnosis Working Group” devised the
recommendations for standard MRM terms based on
architectural features described by the ACR (American
College of Radiology) BIRADS system (Breast Imaging
Reporting and Data System) [8, 9]. Furthermore, Ikeda et
al. developed and standardized the reproducibility in a
lexicon for reporting contrast enhanced breast magnetic
resonance imaging examinations. This lexicon adapted
American College of Radiology Breast Imaging Reporting
and Data System terminology for MRM reporting, includ-
ing recommendations for reporting clinical history, techni-
cal parameters for MRM, descriptions for general breast
C. Sohns (*)
Department of Cardiology and Pneumology, Heart Center,
Georg-August-University of Göttingen,
Robert-Koch-Strasse 40,
37075 Göttingen, Germany
e-mail: csohns@med.uni-goettingen.de
M. Scherrer: W. Staab: S. Obenauer
Department of Radiology, Georg-August-University of Göttingen,
Göttingen, Germany
Eur Radiol (2011) 21:2475–2483
DOI 10.1007/s00330-011-2210-7composition, morphological and kinetically characteristics
of mass lesions or regions of abnormal enhancement,
overall impression and management recommendations [9,
10]. Consequently, the aim of this study was to assess
whether a BI-RADS associated MRM algorithm delivers a
clinical significant prognosis for the diagnosis of breast
tumours.
Materials and methods
Study subjects
In a consecutive series between April 2004 and January
2008, 207 female patients with histological proven
breast lesions have been evaluated. Histology was
predominantly reached by either preoperative wire
localization in MRM or by ultrasound or stereotactic
guided biopsies. In case of malignancy reference
standard was the pathology after surgery. All of the
patients have had a preoperative MR mammography. In
addition all patients underwent a digital mammography
(Senographe 2000D, GE Medical Systems). Patient
details were recorded with the purpose to identify the
mammograms and for accessing demographic informa-
tion. From the request card, logbooks and hospital
database, record was made of age, referring speciality,
date of admission, and anamnesis. Written informed
consent was obtained from each patient. The median
age of the study group was 54 years. Due to different
indications with regards to suspicious breast findings,
including a palpable mass, patients with high risk, and
referrals from other screening investigations like mam-
mography or ultrasound, all patients were referred from
our academic Breast Center. 112 patients had a histo-
logical proven breast cancer and 95 patients had a
histological proven benign tumour (Table 1). In case of a
benign lesion the mean follow up interval was 6 months.
MRM technique
All 207 MRM examinations were performed with the
patient prone in a 1.5-T commercially available system
(Symphony and Sonata, Siemens, Erlangen, Germany)
using a dedicated surface breast coil. The standardized
imaging sequence started with a bilateral axial T2-weighted
turbo spin-echo sequence (GRAPPA factor 2; 8.900/207;
flip angle 90°, spatial resolution 0.8×0.7×3 mm; acquisi-
tion time 2 min 15 s) and a bilateral turbo spin-echo
inversion recovery sequence with reconstruction (GRAPPA
Carcinomas Number (n) Benign Tumors Number (n)
Invasive ductal carcinoma, IDC 32 Ductal hyperplasia, DH 21
Invasive lobular carcinoma, ILC 18 Fibroadenoma, FI 18
Ductal carcinoma in situ, DCIS 17 Fibrocystic changes, FZM 16
Tubular carcinoma, TU 10 Papilloma, PA 9
Lobular carcinoma in situ, LCIS 9 Benign not categorisable, A 8
IDC + Extensiv intraductal carcinoma, EIC 8 Adenosis, SA 13
Ductal and lobular carcinoma, DLC 6 Phyllodes Tumor, PB 3
Mucinous carcinoma, MUC 5 Radial scar, RN 2
Carcinosarcoma, S 2 Atypical Hyperplasia, AH 2
Others 5 Others 3
Total 112 Total 95
Table 1 Distribution of the
histological malignant and
benign lesions
Mass Malignant Benign Total p-value
Shape Number (n) Number (n)
Round 5 5 10 0.5196
Irregular 60 8 68 0.0000***
Lobulated 11 14 25 0.1927
Oval 3 11 14 0.0111*
Table 2 Shape of the mass
enhancement in histological
proven malignant and benign
tumors
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spatial resolution 1.7×1.4×3 mm; acquisition time 2 min
and 33 s) were performed in identical slice positions.
Afterwards an unenhanced axial T1-weighted gradient-echo
sequence (Flash 2D, GRAPPA factor 2; TR/TE 113/5; flip
angle 80°; spatial resolution 1.1×0.9×3 mm; acquisition
time 1 min per measurement) was performed. An intrave-
nous bolus injection of 0.1 mmol/kg body weight gado-
pentetate dimeglumine (Magnevist, Bayer Schering
Pharma, Berlin, Germany) was used at 3 ml/s with an
automatic injector and followed immediately by 20 ml of
saline solution with the same injection rate. 30 s after the
administration of contrast medium, dynamic MRM was
performed with the same parameters and identical tuning
conditions for totally 7 measurements. The contrast-
enhanced images were subsequently subtracted from the
unenhanced images. On the subtraction images the region
of interests (ROI’s) were achieved on a pixel-by-pixel basis
and signal-intensity curves were analysed. The kinetic
behaviour of the lesion was analyzed by ROI in the most
enhancing area. Also maximum intensity projections (MIP)
were displayed.
Image interpretation
The MRM studies were interpreted by two examiners. One
experienced and one trained observer classified the selected
MR images anew, without knowledge of pathology. Neither
was involved in rating the initial MR images, and both were
blindedtotheinitialreportandtotheresultsofthehistological
and mammographic examinations. The rating was performed
in consensus. In the case of different rating, the case was
discussed until agreement was reached. All investigations
were categorised according to BI-RADS: Mass/shape, mass/
margin, mass/enhancement, non-mass/distribution, non-mass/
internalenhancement,symmetry,kineticcurveassessment(24
missing) and T2-weighting (35 missing). These results were
comparedtohistology.Statisticalsignificancefortheaccuracy
of MRM was calculated.
Reference standard
The authors chose the results of the histological examina-
tion as the reference standard for lesion evaluation.
Findings could either be malignant or benign, and the type
of tumour was recorded. All histological examinations were
conducted by board-certified breast pathologists at the
institute of pathology of our university hospital.
Data collection and statistical analysis
Data were recorded in a spreadsheet (Excel, Microsoft,
Redmond, WA). Statistical analysis was performed with the
chi-square and Fisher’s exact tests using statistical software
(SSPS, and MedCalc). According to the level of signifi-
cance (two-sided p-value) asterisks were distributed:
*** p-value<0.0005 (double p-value<0.001, “highly
significant”)
** p-value<0.005 (double p-value<0.01, “significant”)
* p-value<0.025 (double p-value<0.05, “faintly
significant”)
Mass Malignant Benign Total p-value
Margin Number (n) Number (n)
Smooth 3 16 19 0.0004***
Irregular 47 20 67 0.0010**
Spiculated 29 1 30 0.0000***
Table 3 Margin of the mass
enhancement in histological
proven malignant and benign
tumors
Mass Malignant Benign Total p-value
Enhancement Number (n) Number (n)
Rim enhancement 43 1 44 0.0000***
Heterogeneous 35 23 58 0.1664
Homogeneous 1 8 9 0.0092*
Heterogeneous + internal septation 0 5 5 0.0192*
Table 4 Internal enhancement
of the mass enhancement into
histological proven malignant
and benign tumors
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Comparison of benign and malignant tumours
The following tables show the morphological differences
between malignant and benign tumours. For analyzing
reasons we separated into mass and non-mass lesions. It was
proven that 70.5% of the malignant tumours were categorised
as mass, 23.2% as non-mass, and 7 malignant tumours were
inconspicuous at MRM (6.3%; not definitely detected in
MRM, but with positive mammography or ultrasound
investigation, and therefore with histological proven breast
cancer). Out of the 95 benign tumours only 40% delivered a
mass-diagnosis, 35.8%, and 24.2% were considered as
inconspicuous at MRM (Tables 3 and 4). Furthermore
particular attention was paid on the histopathological
diagnosis with regards to the specific BI-RADS criteria.
The specific morphology is presented in the following tables.
Interpretation and reporting of MRM findings on the basis
of the BI-RADS classification
Focus
In this matter it was not possible to give a significant
statement, because only one malignant and one benign
tumour showed a focal enhancement.
Mass
Shape The correlation of shape and diagnosis in mass
enhancement is shown in Table 2 and gives the following
results. 60 out of 68 (88.2%) irregular formed masses are
malignant. 11 out of 14 (78.6%) oval shaped tumours have
a benign histology. 14 of 25 (56%) lobulated tumours were
categorised as benign. Considering the group of 112
malignant tumours, 60 (53.6%) out of them are formed
irregularly.
Margin Correlation between margin and diagnosis in
mass enhancement is given in Table 3. Most of the
malignant lesions have an irregular (42%) or spiculated
(25.9%) margin. Whereas 21.1% of benign lesions are of
irregular margin, only 1.1% are spiculated. A smooth
margin refers to benignity as 16 out 19 tumours of smooth
margin were histological proven benign and only 3 were
malignant.
Enhancement Table 4 shows that the majority of the
malignant tumours had rim enhancement. The sheet points
out, that 43 out of 44 tumours (97.7%) with rim
enhancement were categorised to the malignant group.
Comparing the heterogeneous forms of enhancement, 35
tumours were into the malignant and 23 into the benign
group. Homogeneous enhancement was seen in 88.9% (8/9
Non-mass Malignant Benign Total p-value
Distribution Number (n) Number (n)
Diffuse 14 10 24 0.4133
Multiple regions 4 6 10 0.2761
Regional 5 14 19 0.0101*
Ductal 5 0 5 0.0445
Segmental 3 0 3 0.1564
Dendritic 1 0 1 0.5411
Linear 5 2 7 0.2958
Focal 0 3 3 0.0950
Table 5 Distribution of the non-
mass like-enhancement into
histological proven malignant
and benign tumors
Non-mass Malignant Benign Total p-value
Central enhancement Number (n) Number (n)
Heterogeneous 28 17 45 0.1431
Homogeneous 1 1 2 0.7085
Stippled 5 12 17 0.0298
Clumped 2 3 5 0.4226
Reticular/Dendritic 1 3 4 0.2515
Table 6 Internal enhancement
of the non-mass-like enhance-
ment in histological proven
malignant and benign tumors
2478 Eur Radiol (2011) 21:2475–2483cases) in tumours out of the benign group. Internal
septation refers to benignity (Figs. 1–4).
Non-mass
Distribution There were only a few differences concerning
non-mass between the two groups. However, all lesions
with ductal and segmental distribution were categorised
malignant. On the other hand, all focal lesions showed
benign potential. For regional enhancement a mean signifi-
cance for benignity was reported (Table 5, Fig. 3).
Internal enhancement 28 of 112 malignant tumours (25%)
had a heterogeneous central enhancement. Moreover, a
stippled enhancement was predominantly seen in benign
tumours (Table 6).
Symmetry Table 7 shows the malignant and benign lesions
by means of their symmetry. The table indicates that the
malignant as well as the benign tumours seemed to appear
asymmetrically. Nevertheless, in 9 out of 10 cases symme-
try leads highly significant to a benign tumour.
Kinetic Into the malignant group 69.6% (78/112 tumours)
of the lesions had a medium initial increase of the kinetic
curve. Only 16.1% of the malignant tumours (18/112 cases)
had a fast initial increase. 18 out of 20 tumours (90%) with
a fast kinetic were grouped as malignant (Table 8).
In the benign group 42.1% of the tumours (40/95
cases) showed a medium initial ascent of the curve. Out
of the 16 tumours with slow initial increase 93.7% (15
tumours) were highly significant categorised as benign
(Table 8,F i g .1).
The post initial increase of the signal for malignant
and benign tumours is shown in Table 9. A plateau of
the kinetic curve was seen in 70.5% (79/112 cases) into
malignant lesions, and a wash-out was documented in
15.2% (17 cases). Out of a total number of 121 tumours
with a plateau, 65.2% (79 cases) were categorised as
malignant. In addition 77.3% (17/22 cases) with wash-out
were malignant. Conversely, a further increase of the
kinetic curve was in 90% a marker for a benign tumour
(Table 9).
T2-weighting It was noticeable that 77 (69%) out of the
malignant tumours had an intermediate T2-signal. This
argued in 81.9% for malignancy. By comparison 37 of the
benign tumours (38.9%) had a hyperintense appearance
(Table 10, Figs. 1, 2, 3 and 4).
Discussion
This study demonstrates a high value of a BI-RADS
associated MRM algorithm to deliver a high accuracy for
the diagnosis of breast tumours. The major finding of our
study results which compared MRM findings with histol-
ogy, is that on the basis of the BI-RADS classification an
objective comparability and statement of diagnosis could be
made highly significant.
Non-mass Malignant Benign Total p-value
Symmetry Number (n) % Number (n) %
Symmetric 1 0,9% 9 9,5% 10 0.0044**
Asymmetric 104 92,9% 63 66,3% 167 0.0000***
Inconspicuous 7 6,3% 23 24,2% 30 0.0002***
Total 112 100,0% 95 100,0% 207
Table 7 Symmetry for
histological proven malignant
and benign tumors
Malignant Benign Total p-value
Kinetic/Initial Number (n) Number (n)
Slow 1 15 16 0.0000***
Mean 78 40 118 0.0000***
Fast 18 2 20 0.0004***
Table 8 Initial kinetic curve
assessment (Kinetic) for
histological proven malignant
and benign tumors
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BI-RADS lesion characteristics and the risk of malig-
nancy for mammographic and clinical occult lesions
detected initially on 1.523 MRMs. They concluded that
combinations of BI-RADS lesion descriptors can predict
the probability of malignancy for MRM masses but not
for non-mass like enhancement [2]. In case of mass
lesions, their results act in concert with our data. We
showed as well, that specific BI-RADS criteria are strong
and significant predictors for malignancy in unsuspected
MRM mass lesions. Such confirmation led in about 65%
of cases to a malignant diagnosis (Tables 2, 3 and 4).
However, the combination of several marker and charac-
teristics is useful to determine the likelihood of malignan-
cy. In contrast to the results by Gutierrez et al. we could
observe, that BI-RADS descriptions were as well predic-
tive for malignancy of otherwise unsuspected MRM non-
mass like lesions. Table 5 shows for example, that a non-
mass like enhancement with ductal or segmental distribu-
tion was in 100% malignant.
In addition, our data showing particular BI-RADS
lexicon descriptions to be strong predictors of malignancy,
support recent work by Liberman et al. Their group
investigated 427 lesions by MRM with dutcal enhance-
ment. 80% out of the benign tumours had a plateau into the
contrast-enhancement dynamic and 89% an isointensic
signal into the T2-weighting [11]. Tozaki et al. described
the PPV and NPVof focal masses. The main criterion for a
malignant lesion was heterogeneous enhancement (96%),
while benign tumours showed inconspicuous margin and
form in 82%. The highest PPV for a malignant enhance-
ment had lesions with spiculated margin (100%), irregular
form (97%) and a heterogeneous enhancement without
internal septation (97%). The highest PPV for benignity
was found in tumours with oval mass (88%), homoge-
neous mass-enhancement (87%) and heterogeneous mass-
enhancement with internal septation (86%). Combination
of several specifications lead to a PPV of 100% for
tumours with spiculated rim as well as for tumours with
heterogeneous enhancement and post initial wash-out if
those lesions were out of the group with oval margin
[12].
However, non-mass like enhancement was identified as a
challenging subgroup causing a high proportion of false-
positive diagnoses at diagnostic MRM. In several cases this
lead to unnecessary biopsy [13]. In a further study by
Tozaki et al. they investigated tumours without mass
findings and PPVs were as well compared with each other.
They concluded that most of the benign tumours were
linear (50%) and had a homogeneous internal pattern
(42%). In contrast, most of the malignant tumours were
segmental (56%), heterogeneous (44%) and had a rim
A  B 
C  E D
Fig. 1 Mass enhancement into the right breast (lobulated shape, irregular margin, heterogeneous enhancement) with hyperintensic T2-result. T1-
weighting (a), T2-weighting (b), subtraction (c), MIP-Reconstruction (d), Kinetic curve assessment (e). Histology: Phyllodes tumour
Malignant Benign Total p-value
Kinetic/Post initial Number (n) Number (n)
Plateau 79 42 121 0.0000***
Wash-out 17 5 22 0.0170*
Further increase 1 9 10 0.0044**
Table 9 Post initial kinetic
curve assessment (Kinetic) for
histological proven malignant
and benign tumors
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T2-result Number (n) % Number (n) %
Hyperintensic 11 9% 37 38,9% 48 0.0000***
Intermediate 77 69% 17 17,9% 94 0.0000***
Inconspicuous 7 6% 23 24,2% 30 0.0002***
Missing 17 15% 18 18,9% 35 0.2958
Total 112 100,0% 95 100,0% 207
Table 10 T2- weighting for
histological proven malignant
and benign tumors
B A
D C
Fig. 2 Non-mass like
enhancement into the right
breast (regional,
heterogeneous enhancement),
intermediate T2-result.
T1- weighting (a), T2-
weighting (b), subtraction (c),
MIP-Reconstruction (d).
Histology: Invasive lobular
carcinoma
A  B C
Fig. 3 Non-mass like enhancement into the left breast (regional, heterogeneous enhancement), hyperintensic T2-result. T1- weighting (a), T2-
weighting (b), Subtraction (c). Histology: Ductal hyperplasia
A  B
C  D
Fig. 4 Mass enhancement (irregular shape, irregular margin, heterogeneous) in the right breast with intermediate signal in T2. T1- weighting (a),
T2- weighting (b), subtraction (c), MIP-Reconstruction (d). Histology: Radial scar
Eur Radiol (2011) 21:2475–2483 2481enhancement. The highest PPV had carcinomas with a
segmental distribution (100%), rim enhancement (100%)
and grouped internal compaction (88%) [14]. This acts in
concert with our results. Mass enhancement (68%) was
significant for malignancy. This was confirmed by high
significance (Table 2). A similar picture was shown for
tumours without mass enhancement, 56.6% of them were
benign. In this context, it has to be mentioned that 23%
of the inconspicuous MR mammograms had malignant
and 77% benign lesions (Table 2). Furthermore, our
results indicated that 88% of the tumours with irregular
shape were highly significant malignant. Those tumours
with an oval or lobulated shape were in 78.6% (oval) and
56% (lobulated) benign. However, in these cases only a
mean significance was reached. This leads to the conclu-
sion that a lesion with an irregular shape is with the utmost
probability malignant. In contrast, tumours with oval or
lobulated shape suspect to be benign, without verifiable
significance (Table 2). This is absolutely in line with
former studies [11–14].
There was a strong tendency for tumours with irregular
or spiculated margins to be malignant. Highly significant
for benignity were tumours with smooth margin (84.2%;
Table 3). If a lesion showed rim enhancement it was highly
significant malignant (97.7%). Tumours were significantly
benign if there was a homogeneous enhancement (88.9%)
or a heterogeneous enhancement with internal septation
(100%; Table 4).
A non-mass like lesion with ductal or segmental
distribution was in 100% malignant. Diffuse distribution
was commonly seen within malignant tumours. However, it
was not possible to constitute a distinct statistical statement
(Table 5).
This corresponds to the study by Baltzer et al. which
aimed to identify criteria for false-positive MRM findings
in clinical practice. They concluded that non-mass like
enhancement was the main cause for those findings.
Furthermore, in their analysis the BI-RADS descriptions
were not sufficient for differentiating malignant and benign
non-mass like enhancement [15].
Evidence-based algorithms are needed to guide the
radiologist through image assessment and to describe
morphologic features. Thus, concerning the form of
internal enhancement the range was essentially exceeded.
28 out of the malignant tumours showed heterogeneous
enhancement, this lead to significance to malignancy
only in 62%. Marks for benignity were reticular (75%)
and stippled/punctuated enhancement (70.58%). Whereas
only 3.2% and 12.6% out of all benign tumours showed
this pattern. Consequently, a significant statement could
not be announced (Table 6). In addition, symmetry was
very important to deliver a prognosis. 90% out of the
symmetric appeared enhancement (9.5% of the benign
tumours) were significantly benign. Asymmetric appeared
enhancement was highly significant for malignancy
(Table 7).
A number of investigations have been conducted to
introduce and describe the kinetic features of breast lesions
[12, 13]. Tumours with a mean or fast signal increase had a
high significance to be malignant in 66% or 90%. It was
well-defined, that tumours with a slow signal increase were
highly significant benign (in 94%). Furthermore, it was
shown that lesions with a plateau or a wash-out were
significant malignant. Only 44% of the benign group
showed a plateau (Tables 8 and 9). Within the T2-
weighting a strong tendency was seen, that tumours with
an intermediate signal were in 82% highly significant
malignant. On the other hand, a hyperintense signal in the
T2- weighting was in 77% an indicator for benignity
(Table 10).
Finally weconclude, based on the BI-RADS classification,
that an objective comparability and highly significant state-
ment of diagnosis can be made [2–6, 12–16]. The combina-
tion of several marker and characteristics is still essential to
determine malignancy. Due to numerous false-negative and
false-positive MRM-results histology is still essential.
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